What is Hexarelin? What it does, benefits and what the evidence shows

Hexarelin is a synthetic six-amino-acid peptide that stimulates the pituitary gland to release a large, short burst of growth hormone. It was studied in a set of small human studies in the 1990s and early 2000s, mostly single-session experiments in healthy volunteers and patients, and it has never been approved by a regulator we could find for any use. The best-documented effects are the growth hormone pulse itself and a brief, acute bump in heart pumping strength; the claims that sell it (muscle, fat loss, anti-aging) have no controlled human trial behind them.

What hexarelin is and how it works

Hexarelin is a hexapeptide (six amino acids, including two non-natural D-form residues) that stimulates growth hormone release in vitro and in vivo (Imbimbo et al., European Journal of Clinical Pharmacology, 1994). It belongs to the growth hormone-releasing peptide (GHRP) family and was described in the literature as an analog of an earlier compound, GHRP-6 (Giustina et al., Endocrine Research, 1995).

Like other GHRPs, it works by activating receptors for ghrelin, the stomach hormone that signals hunger, in the pituitary and hypothalamus. In a review of human studies, Ghigo and Arvat describe these compounds as acting on specific receptors mainly at the hypothalamic level, where they behave as functional somatostatin antagonists and enhance the activity of growth hormone-releasing hormone (GHRH) neurons (Ghigo and Arvat, Endocrine, 2001). Put simply, hexarelin doesn't supply growth hormone; it prompts your pituitary to release its own, and it needs a working pituitary to do that. In adults with severe growth hormone deficiency the response was negligible (peak of about 2 versus about 46 micrograms per liter in healthy controls) (Bisi et al., European Journal of Pharmacology, 1999).

Hexarelin is also unusual in the GHRP family for a second target. A 2014 review reports that a non-ghrelin receptor called CD36 has been identified as a specific cardiac receptor for hexarelin that mediates its heart-protective effects (Mao et al., Journal of Geriatric Cardiology, 2014). That is the basis for most of the cardiovascular research below.

Hexarelin isn't a drug you can get with a prescription. We found no approval from any regulator, and it is a named growth hormone-releasing peptide on the World Anti-Doping Agency's 2026 Prohibited List, under its other name examorelin (WADA Prohibited List 2026).

What people use it for

What the research actually shows

The growth hormone pulse is real

The clearest finding is the hormone response. In a double-blind, placebo-controlled study in 12 healthy men, hexarelin raised growth hormone in a dose-dependent way, peaking at around half an hour and returning to baseline within about four hours; the response at the highest dose studied was close to the maximal response the authors could model (Imbimbo et al., 1994). In 12 healthy young volunteers it produced roughly twice the growth hormone response of an equal-weight dose of GHRH, and the response was highly reproducible from one session to the next (Ghigo et al., Journal of Clinical Endocrinology & Metabolism, 1994).

It isn't a clean growth hormone signal, though. In a dose-response study in healthy men, the same doses that released growth hormone also raised prolactin and cortisol in a dose-dependent way (Massoud et al., 1996). A separate study in 15 healthy men found hexarelin raised ACTH and cortisol about as much as CRH, the body's own stress-axis trigger, and produced a small rise in appetite (Korbonits et al., 1999). That matters if you have seen hexarelin compared with ipamorelin, which is marketed on being more selective; our ipamorelin guide covers what is and isn't shown there.

The response fades with repeated use

This is the finding buyers most often miss. In a study of repeated hexarelin dosing over a period of months in healthy older adults, the growth hormone response to hexarelin fell significantly compared with the start, from a mean area under the curve of 19.1 at baseline to 10.5 at week 16 in 12 healthy elderly people given twice-daily injections for 16 weeks. The authors described the attenuation as partial and reversible: four weeks after stopping, the response was back to baseline (Rahim and Shalet, Growth Hormone & IGF Research, 1998). In the companion report from the same study, IGF-I (the main downstream marker of growth hormone activity) did not change significantly, and neither did total body fat, lean body mass or bone density; the authors concluded that the biological impact on the growth hormone axis "seems to be minimal" and that the therapeutic potential of chronic use needs further investigation (Rahim et al., Journal of Clinical Endocrinology & Metabolism, 1998).

So the one human study that looked at what repeated use does to body composition found nothing measurable. That is a small study in older adults, not proof it does nothing in everyone, but it is the only such data, and it doesn't support the muscle and fat-loss marketing.

Diagnostic use: a research tool, not an approved test

Two studies looked at hexarelin as a way to diagnose growth hormone deficiency in adults. One combined a low amount of hexarelin with GHRH and found the test was as sensitive as the standard insulin tolerance test, once appropriate cut-off limits were used, across 19 patients and normal volunteers (Gasperi et al., 1999). The other, in 19 patients with possible pituitary disease, concluded hexarelin could be a useful screening test for growth hormone deficiency but not for the cortisol axis (Korbonits et al., 1999). Both are small and neither made hexarelin a standard test; a related peptide, GHRP-2, was later approved in Japan for exactly that diagnostic purpose (see our GHRP-2 guide).

The heart: intriguing, acute, and small

The cardiac work is the most unusual part of the hexarelin story. In seven men with growth hormone deficiency and nine healthy controls, a single intravenous hexarelin dose raised left ventricular ejection fraction (a measure of pumping strength) in both groups; because the deficient patients barely released any growth hormone, the authors argued the effect was independent of it (Bisi et al., 1999). In 24 men having bypass surgery, hexarelin under anesthesia raised ejection fraction, cardiac index and cardiac output for up to 90 minutes, while GHRH, growth hormone and placebo did not (Broglio et al., 2002).

But those are single-dose, short-lasting effects in small groups. In 13 patients with severe heart failure, hexarelin raised ejection fraction in the five with ischemic disease but not in the eight with dilated cardiomyopathy (Imazio et al., European Journal of Heart Failure, 2002). And a bump in ejection fraction over an hour is not a treatment for heart disease. The longer-term heart protection reported in animals, such as rats, has not been shown in people; the 2014 review itself calls hexarelin a "promising" candidate rather than a proven one (Mao et al., 2014). Other lab reports, in cells and rodents, cover the kidney, blood vessels and nerves; they are early findings only and we don't grade them here.

Everything else

We found no controlled human trial of hexarelin for muscle growth, fat loss, sleep, recovery or anti-aging. Those claims come from the mechanism (more growth hormone) and from anecdote. The one repeated-dosing study we found, above, points the other way.

Side effects and risks

There is no human safety database for hexarelin. The studies above were short and small, and they don't add up to a safety profile for the way it's used on the grey market. What they do show:

• Off-target hormones. Cortisol, ACTH and prolactin rose alongside growth hormone in healthy volunteers (Massoud et al., 1996; Korbonits et al., 1999). Nobody has studied what repeated exposure to that does over a long time.
• Appetite. A small increase in hunger was reported after a single dose (Korbonits et al., 1999), consistent with its ghrelin-receptor action.
• Fading effect. The growth hormone response dropped with repeated use (Rahim and Shalet, 1998), so more of it doesn't reliably mean more effect.
• Heart effects are acute and unstudied long-term. The cardiac trials were under medical monitoring, some under anesthesia. They tell you nothing about unsupervised use.
• Sport. It is prohibited at all times for athletes under the WADA list cited above.

On the buying side, the risks are the ones our data shows for every peptide: purity, fill amount versus the label, and endotoxin. See endotoxin in research peptides and underdosed peptides.

What the lab tests show

As of September 29, 2026, VendorVerify's database has no lab results for hexarelin. That doesn't mean vials are good or bad; it means nobody has submitted a report we can count. If you have had a hexarelin vial tested, submitting the report is the fastest way to change that, and the first few reports will tell buyers more than any guess can.

Because we don't have enough lab data on this compound to rank vendors for it, here are the highest-ranked vendors across all compounds right now. A vendor's overall record is a signal, not a guarantee for a compound they have never had tested.

Buying smarter

With no compound-specific data, the checks that matter most are the general ones. Read the vendor's full record and how many reports sit behind it, treat a vendor-posted COA as a starting point (see how to read a peptide COA and fake peptide COAs), and consider paying for an independent identity, purity and quantity test on your own vial (how to get a peptide tested). Hexarelin is a lesser-tested compound, so a wrong peptide sold under the right name is a real possibility; identity testing is worth the money here.

If a report comes back with a fail, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify. Buyers researching hexarelin often also look at GHRP-2, ipamorelin, CJC-1295 and sermorelin. Our peptide hub lists every compound we track, and what are grey market peptides explains the market itself.

Database figures are from VendorVerify as of September 29, 2026. This isn't medical advice; hexarelin is sold for research use only and has not been approved for any use that we could find.